Career Possibilities Panel & Speed Networking: Commercial, Medical Affairs, Market Access

In the world of business, careers are no longer linear or predictable. What was once a clearly sign-posted path as you progressed through milestones, a career road map is now circuitous presenting new challenges and opportunities at every bend. Life-long careers in one sector or one company are becoming a rarity as new technologies and shifting social norms disrupt traditional careers. Both employers and employees are seeking more diversity of experience, lifestyle flexibility and alternative paths.

This panel is designed to help you think about your career path and the different options that are open to you. The panel will have an informational interview type feel with panelists sharing their career paths, a look at what their job entails, transferrable skills for those looking to make a change, tips for uncovering opportunities, advice for others, and how to make brave leaps. 

Panelists include:
 - Eboni Chambers, Regional Medical Director, Horizon
 - Sarah Gheuens, Chief Medical Officer, EVP, Agios Pharmaceuticals
 - Kristie Kapinas, CF Medical Science Liaison, Vertex Pharmaceuticals
 - Erin Mistry, 
Senior Vice President of Market Access, Government affairs and Trade at CorMedix Inc.


Download the Flyer


Date and Time:  
March 16, 2022
6:15-7:45 PM EST

5 mins: Welcome
60 mins: Panel discussion
10 mins: Small group speed networking
5 mins: Learnings
10 mins: Small group speed networking




Members, Students, Postdocs: $5; Non-Members: $15

Given our mission is to promote women's development in STEM we would like to offer a free spot in our workshops to those in transition between jobs or who cannot afford the ticket price. Please contact [email protected] if you qualify.


Register Here



Check out the other events in this series


Panelist Bios

Sarah Gheuens, M.D., Ph.D. joined Agios in December 2019 and became chief medical officer in September 2021. She previously served as Agios’ head of clinical development for the genetically defined disease programs, as well as the interim head of regulatory affairs. She has been instrumental in completing the pivotal Phase 3 program for pyruvate kinase deficiency and leading simultaneous regulatory submissions to the FDA and EMA in this indication, as well as designing the pivotal programs for thalassemia, sickle cell disease and the pediatric indications. Prior to joining Agios, Dr. Gheuens worked at Biogen, where she held roles of increasing responsibility in safety, medical affairs and clinical development. Her work was critical for the approval of SPINRAZA®. Before joining Biogen, Dr. Gheuens worked at Beth Israel Deaconess Medical Center (BIDMC), taking care of patients with HIV and neurological complications and doing research on progressive multifocal leukoencephalopathy. Dr. Gheuens received her medical degree from the Free University of Brussels (VUB), Belgium, and completed her neurology residency at the University Hospital of the Free University of Brussels, Belgium, followed by an HIV/neurology fellowship at BIDMC, Boston, Mass., USA. She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master’s in Medical Sciences from Harvard Medical School.

Kristie Kapinas is a PhD-trained scientist in Biomedical Sciences in endocrinology. After postdoctoral fellowships focusing on stem cell pluripotency and immunology, she transitions to biotech roles in sales and business development in New England. Using her territory and account management experience, combined with her scientific and medical knowledge background, she was able to find her first role as a disease educator and MSL with Vertex Pharmaceuticals with a focus on rare disease. She had additional roles as Global Director of Advocacy and Alliances at a small biotech, and two other Senior MSL roles in Rheumatology, Hepatitis, and vaccines. She since returned to Vertex as the Sr MSL in the Southwest United States.

Eboni D. Chambers, Ph.D., M.P.A. is the Nephrology Regional Medical Director for Horizon Therapeutics. Dr. Chambers joined Horizon in 2021 to develop Nephrology Key Opinion Leaders through the implementation of clinical and educational strategies in support of Horizon-sponsored trials and educational initiatives. In her short time with the company, her efforts have significantly expanded the presence of Medical Affairs in the Mid- Atlantic region. Prior to this role, Dr. Chambers was a Strategic Account Associate at Precision Medicine Group where she was instrumental in the development of Field Medical Strategy for small molecules and biologics through all phases of the product life cycle within rheumatology, immunology, and rare disease indications. Dr. Chambers is passionate about communicating medical and scientific advances, developing medical strategy, and addressing unmet needs for patient populations. In 2018, Eboni received both her Ph.D. in Pathobiology and M.P.A. in Public Affairs from Brown University- the first-ever dual Pathobiology Ph.D., M.P.A. degree awarded from the University. Her cross-disciplinary background in biomedical science, health economics, and public affairs has been influential in her approach to solve complex problems that impact underserved patient populations.

Erin Mistry is an experienced biotech executive with a focus on global commercial strategy, portfolio prioritization, brand development, pricing, policy, and payer positioning. Currently Senior Vice President of Market Access, Government affairs and Trade at CorMedix Inc. Ms. Mistry is leading a variety of policy and commercial efforts to support an antimicrobial product launch in the near future. Previously, Ms. Mistry worked for Duke University Health System on formulary management and the development and implementation of system wide quality metrics before spending several years at MedImmune. While at MedImmune Ms. Mistry focused on the global rollout and reimbursement of FluMist and Synagis prior to and during their acquisition by AstraZeneca. In 2012, Ms. Mistry went into management consulting which culminated in global P&L responsibility focused on emerging, mid, and large biopharma companies to enhance their portfolio and value optimization. Specifically she led and negotiated with executive teams and their boards on launch pricing scenarios of more than a dozen products across a range of indications, including oncology, rare/orphan diseases, diabetes, infectious disease, metabolic disorders, ophthalmology, CNS, and cardiovascular. Ms. Mistry received both her M.S. in Biomechanical Engineering and B.S. in Industrial Engineering, Healthcare track from North Carolina State University. She has testified formally on Drug Pricing and has recently obtained several certifications from Harvard Business School Executive Education program. Erin is currently certified as a Six Sigma Black Belt and was a 3-year Captain of the Women’s soccer team at N.C. State University.